Modelled DT Structure
Method:homology modeling
Template PDB:7BP3_A
Identity:45.61%
Minimized Score:-944.326 kcal/mol
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0107 | ||||
Gene Name | SLC16A3 | ||||
Protein Name | Monocarboxylate transporter 4 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method:homology modeling Template PDB:7BP3_A Identity:45.61% Minimized Score:-944.326 kcal/mol Detail: Structure Info |
||||
Synonyms | MCT 4; MCT4; SLC16A3; Solute carrier family 16 member 3 | ||||
DT Family | Major Facilitator Superfamily (MFS) | ||||
Monocarboxylate Transporter (MCT) Family | |||||
Tissue Specificity | Highly expressed in skeletal muscle. | ||||
Function | This proton-linked monocarboxylate transporter catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. | ||||
Endogenous Substrate(s) | Monocarboxylates; Lactate; pyruvate; Branched-chain oxo acids | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 4.0) |
|||||
(α) Tissue Distribution Level of Monocarboxylate transporter 4 |
|||||
(β) Cell Distribution Level of Monocarboxylate transporter 4 |
|||||
(γ) Organelle Distribution Level of Monocarboxylate transporter 4 |
|||||
Regulatory Variability Data of This DT |
|||||
(α) Microbiota Influence of Monocarboxylate transporter 4 |
|||||
(β) Post-translational Modification of Monocarboxylate transporter 4 |
|||||
(γ) Transcriptional Regulation of Monocarboxylate transporter 4 |
|||||
(δ) Epigenetic Regulation of Monocarboxylate transporter 4 |
|||||
(ε) Exogenous Modulation of Monocarboxylate transporter 4 |
|||||
Structural Variability Data of This DT |
|||||
(β) Inter-species Structural Differences |
|||||
(γ) Outward/inward-facing Conformation |
|||||
(δ) Xenobiotics-regulated Structural Variability |
|||||
General Variability Data of This DT |
|||||
(α) Genetic Polymorphisms of Monocarboxylate transporter 4 |
|||||
(β) Disease-specific Protein Abundances of Monocarboxylate transporter 4 |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Endogenous Metabolites (EMs) Handled by This DT |
|||||
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 1 EMs in Total | ||||
EM Name | PubChem CID | Detail | Experimental Material | Ref | |
L-lactate | EM Info | Identified using MCT4-attenuated mice | [1] | ||
Drug-DT Affinity Assessed by Cell Line |
|||||
Investigative Drug |
Click to Show/Hide the Full List of Drug: 3 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Milchsaure | Investigative | Drug Info | Oocytes-MCT4 | Km =28 microM | [2] |
Milchsaure | Investigative | Drug Info | Oocytes-MCT4 | Km =28 microM | [2] |
Milchsaure | Investigative | Drug Info | Oocytes-MCT4 | Km =28 microM | [2] |
References | |||||
1 | GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. Int J Cancer. 2017 Nov 15;141(10):2131-2142. | ||||
2 | Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 2000 Dec 1;529 Pt 2:285-93. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.